Dhungana Santosh, Criner Gerard J
Department of Thoracic Medicine and Surgery, Temple Lung Center, Lewis Katz School of Medicine at Temple University, Philadelphia, PA, USA.
Int J Chron Obstruct Pulmon Dis. 2017 Aug 3;12:2307-2312. doi: 10.2147/COPD.S89482. eCollection 2017.
Long-acting bronchodilators are the mainstay of the treatment of COPD. With the advent of several combination inhalers with long-acting antimuscarinic agents (LAMAs) and long-acting beta agonists (LABAs), the choice of therapy in the treatment of COPD has been ever expanding. With the focus of COPD management shifting from FEV-based treatment escalation to symptoms and risk-based treatment, we are seeing a paradigm shift in COPD treatment with early introduction of LAMA-LABA combination as a single inhaler. Glycopyrronium/formoterol fumarate fixed-dose combination formulated in a familiar metered-dose inhaler format using proprietary co-suspension technology is a new option on the market. We purport to discuss the evidence behind the approval of the drug combination and its place in therapy.
长效支气管扩张剂是慢性阻塞性肺疾病（COPD）治疗的主要药物。随着几种含有长效抗胆碱能药物（LAMA）和长效β受体激动剂（LABA）的联合吸入器的出现，COPD治疗的药物选择一直在不断扩大。随着COPD管理的重点从基于第一秒用力呼气容积（FEV）的治疗升级转向基于症状和风险的治疗，我们看到COPD治疗出现了范式转变，即早期引入LAMA-LABA联合单一吸入器。使用专利共悬浮技术以熟悉的定量吸入器形式配制的格隆溴铵/富马酸福莫特罗固定剂量组合是市场上的一种新选择。我们旨在讨论该药物组合获批背后的证据及其在治疗中的地位。
